FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2909079683> ?p ?o ?g. }

• W2909079683 abstract "Bortezomib is a proteasome inhibitor, approved for treating newly diagnosed and relapsed multiple myeloma (MM). This realworld, multicenter, observational, non-interventional study of bortezomib was designed to collect and analyze prospective data in Taiwanese patients with relapsed or refractory MM. The primary endpoints included clinical effectiveness outcomes (disease response, disease progression [PD], time-to-response, time-toprogression, response duration, and overall survival [OS]). Secondary endpoints were safety and healthcare resource utilization. Total 100 patients (median [range] age 64.9 [37.0-85.5] years) were enrolled; 47 patients completed the study. Of the withdrawn patients (n=53), there were 48 deaths (PD-related death: n=35, adverse events [AEs]-related: n=12, other reason: n=1), and 5 due to loss to follow-up. Four patients in Cycle 1, 6 patients each in Cycle 2 and 5, 7 in Cycle 3, 10 patients in Cycle 4, 5 patients in Cycle 6, and 3 patients each in Cycle 7 and 8 achieved overall response during the study. Time-to-response was 4.68 months (95%CI: 3.2, NE) and response duration was 10.08 months (95%CI: 2.3, 28.6). Median OS was 9.8 months (95%CI: 3.8, 13.7), and median time-to-progression was 11.3 months (95%CI: 6.2, 20.2). Most common non-hematological AEs were diarrhea (n=32) and hypoesthesia (n=25); most common hematological AE was thrombocytopenia (n=18). Efficacy and safety profile of bortezomib in Taiwanese patients with MM was similar to global and other Asian population. Study provides a critical insight on use of bortezomib in realworld clinical practice, which can be helpful for Taiwanese healthcare providers’ decision-making processes." @default.
• W2909079683 created "2019-01-25" @default.
• W2909079683 creator A5014386297 @default.
• W2909079683 creator A5023816493 @default.
• W2909079683 creator A5028706470 @default.
• W2909079683 creator A5035976962 @default.
• W2909079683 creator A5039440415 @default.
• W2909079683 creator A5041872254 @default.
• W2909079683 creator A5045089058 @default.
• W2909079683 creator A5048450774 @default.
• W2909079683 creator A5058608094 @default.
• W2909079683 date "2019-01-18" @default.
• W2909079683 modified "2023-10-14" @default.
• W2909079683 title "Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma" @default.
• W2909079683 cites W1497973518 @default.
• W2909079683 cites W1976152446 @default.
• W2909079683 cites W1977194024 @default.
• W2909079683 cites W1978377409 @default.
• W2909079683 cites W1978850023 @default.
• W2909079683 cites W2009888511 @default.
• W2909079683 cites W2014946770 @default.
• W2909079683 cites W2042190403 @default.
• W2909079683 cites W2065088660 @default.
• W2909079683 cites W2076028786 @default.
• W2909079683 cites W2079153642 @default.
• W2909079683 cites W2088929163 @default.
• W2909079683 cites W2093678068 @default.
• W2909079683 cites W2096207943 @default.
• W2909079683 cites W2107154392 @default.
• W2909079683 cites W2108235071 @default.
• W2909079683 cites W2111650326 @default.
• W2909079683 cites W2123077018 @default.
• W2909079683 cites W2124560610 @default.
• W2909079683 cites W2132485651 @default.
• W2909079683 cites W2134168744 @default.
• W2909079683 cites W2138694160 @default.
• W2909079683 cites W2142793991 @default.
• W2909079683 cites W2165065963 @default.
• W2909079683 cites W2167310857 @default.
• W2909079683 cites W2316083657 @default.
• W2909079683 cites W4211037848 @default.
• W2909079683 doi "https://doi.org/10.4081/oncol.2019.377" @default.
• W2909079683 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6379781" @default.
• W2909079683 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30858932" @default.
• W2909079683 hasPublicationYear "2019" @default.
• W2909079683 type Work @default.
• W2909079683 sameAs 2909079683 @default.
• W2909079683 citedByCount "4" @default.
• W2909079683 countsByYear W29090796832019 @default.
• W2909079683 countsByYear W29090796832020 @default.
• W2909079683 countsByYear W29090796832021 @default.
• W2909079683 crossrefType "journal-article" @default.
• W2909079683 hasAuthorship W2909079683A5014386297 @default.
• W2909079683 hasAuthorship W2909079683A5023816493 @default.
• W2909079683 hasAuthorship W2909079683A5028706470 @default.
• W2909079683 hasAuthorship W2909079683A5035976962 @default.
• W2909079683 hasAuthorship W2909079683A5039440415 @default.
• W2909079683 hasAuthorship W2909079683A5041872254 @default.
• W2909079683 hasAuthorship W2909079683A5045089058 @default.
• W2909079683 hasAuthorship W2909079683A5048450774 @default.
• W2909079683 hasAuthorship W2909079683A5058608094 @default.
• W2909079683 hasBestOaLocation W29090796831 @default.
• W2909079683 hasConcept C121332964 @default.
• W2909079683 hasConcept C126322002 @default.
• W2909079683 hasConcept C141071460 @default.
• W2909079683 hasConcept C142424586 @default.
• W2909079683 hasConcept C197934379 @default.
• W2909079683 hasConcept C203092338 @default.
• W2909079683 hasConcept C2776364478 @default.
• W2909079683 hasConcept C2777478702 @default.
• W2909079683 hasConcept C2778367456 @default.
• W2909079683 hasConcept C2778822529 @default.
• W2909079683 hasConcept C2779134260 @default.
• W2909079683 hasConcept C535046627 @default.
• W2909079683 hasConcept C71924100 @default.
• W2909079683 hasConcept C87355193 @default.
• W2909079683 hasConcept C90924648 @default.
• W2909079683 hasConceptScore W2909079683C121332964 @default.
• W2909079683 hasConceptScore W2909079683C126322002 @default.
• W2909079683 hasConceptScore W2909079683C141071460 @default.
• W2909079683 hasConceptScore W2909079683C142424586 @default.
• W2909079683 hasConceptScore W2909079683C197934379 @default.
• W2909079683 hasConceptScore W2909079683C203092338 @default.
• W2909079683 hasConceptScore W2909079683C2776364478 @default.
• W2909079683 hasConceptScore W2909079683C2777478702 @default.
• W2909079683 hasConceptScore W2909079683C2778367456 @default.
• W2909079683 hasConceptScore W2909079683C2778822529 @default.
• W2909079683 hasConceptScore W2909079683C2779134260 @default.
• W2909079683 hasConceptScore W2909079683C535046627 @default.
• W2909079683 hasConceptScore W2909079683C71924100 @default.
• W2909079683 hasConceptScore W2909079683C87355193 @default.
• W2909079683 hasConceptScore W2909079683C90924648 @default.
• W2909079683 hasIssue "1" @default.
• W2909079683 hasLocation W29090796831 @default.
• W2909079683 hasLocation W29090796832 @default.
• W2909079683 hasLocation W29090796833 @default.
• W2909079683 hasLocation W29090796834 @default.
• W2909079683 hasOpenAccess W2909079683 @default.
• W2909079683 hasPrimaryLocation W29090796831 @default.
• W2909079683 hasRelatedWork W1989734946 @default.

• next